Compare Heron Therapeutics Inc (HRTX) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Zimmer Biomet Holdings Inc — how do they compare? Heron Therapeutics Inc trades at $0.46 (market cap $91.46M), while Zimmer Biomet Holdings Inc trades at $90.03 (market cap $17.36B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 189.8× Heron Therapeutics Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.07% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | ZBH | |
|---|---|---|
Market Cap | $91.46M | $17.36B |
Sector | Health | Health |
52-Week High | $1.96 | $107.71 |
52-Week Low | $0.39 | $79.58 |
Enterprise Value | $189.36M | $24.40B |
Dividend Yield | — | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.48, up 2.06% today, with a bullish technical signal but mixed earnings performance. The company reported Q1 2026 revenue of $151M but missed EPS estimates with a $0.04 loss. Despite negative net income margins, analyst consensus remains overwhelmingly bullish with 18 buy ratings. Recent patent litigation developments and seasonal pressures have impacted quarterly results.
Outlook remains challenged by ongoing losses and competitive pressures, though strong analyst support suggests potential upside if execution improves. Key risks include patent litigation outcomes, cash flow sustainability, and ability to achieve profitability. The stock's low price presents speculative opportunity but requires careful risk management.
Zimmer Biomet (ZBH) trades at $88.92, down 2.41% on the day, with a bearish technical signal but strong fundamentals including a 70.03% gross margin and three consecutive quarterly EPS beats. Revenue grew to $8.23B in 2025, though net income margin compressed to 8.56%. The company announced a $1 billion share repurchase increase and expansion in India, while maintaining a dividend.
The stock offers a 10% upside to the $97.67 consensus price target, supported by value metrics and operational strength, but faces risks from rising debt levels and competitive pressures. Analyst sentiment is mixed with 40% buy ratings, suggesting cautious optimism amid near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
